Invaluable Work

OB Pharma is developing new molecules for the treatment of epilepsy and seizure disorders that are particularly difficult to manage such as those arising from traumatic brain injury.

Our late cofounder and CSO, Dr. Michael Poulter was a preeminent neuroscientist and expert in the field of epilepsy research with our preclinical program at the University of Western Ontario and the Robarts Research Institute, one of Canada’s premier epilepsy centers.

OB Pharma is currently seeking venture partners to complete its preclinical program in order to file an IND with the U.S. FDA and a CTA with Health Canada and initiate clinical trials.

If you are an individual or corporate investor, and you are interested in learning more about our development program, please contact us.

LogoVector Investors